Recent advances in cancer immunotherapy—ranging from immune-checkpoint blockade
therapy to adoptive cellular therapy and vaccines—have revolutionized cancer treatment …

Globally, liver cancer is the most frequent fatal malignancy; in the United States, it ranks fifth.
Patients are often diagnosed with liver cancer in advanced stages, contributing to its poor …

Neoantigens are peptides derived from non-synonymous mutations presented by human
leukocyte antigens (HLAs), which are recognized by antitumour T cells,,,,,,,,,,,,–. The large …

Therapeutic reinvigoration of tumor-specific T cells has greatly improved clinical outcome in
cancer. Nevertheless, many patients still do not achieve durable benefit. Recent evidence …

Metastasis is the primary cause of cancer-related deaths. Although The Cancer Genome
Atlas has sequenced primary tumour types obtained from surgical resections, much less …

Recent advances in cancer treatment have emerged from new immunotherapies targeting T-
cell inhibitory receptors, including cytotoxic T-lymphocyte associated antigen (CTLA)-4 and …

Spaceflight can change metabolic, immunological, and biological homeostasis and cause
skin rashes and irritation, yet the molecular basis remains unclear. To investigate the impact …

T cell Ig and ITIM domain (TIGIT) is an inhibitory receptor expressed by activated T cells,
Tregs, and NK cells. Here, we determined that TIGIT is upregulated on tumor antigen …

Cancer immunotherapy shows promising potential in future cancer treatment but
unfortunately is clinically unsatisfactory due to the low therapeutic efficacy and the possible …

In this Timeline, we describe the characteristics of tumour antigens that are recognized by
spontaneous T cell responses in cancer patients and the paths that led to their identification …